Grade: Pharmaceutical Grade

Factory Location: QUANZHOU

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Favipiravir, as a new broad-spectrum anti-rna virus drug, was approved to be marketed in Japan in March 2014 for the antiviral treatment of influenza a and b.

Research shows that in addition to influenza virus, familavir also shows good antiviral activity against a variety of RNA viruses, such as ebola virus, sand virus, bunya virus, rabies virus.Recent studies have shown that fabivir has a certain inhibitory effect on COVID-19.